Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsBCBS South Dakota Ocaliva Coverage | OpenPayer
    Ask Trek AI about this page
    CurrentBlue Cross Blue Shield - South DakotaPolicy 05.02.02

    Ocaliva (obeticholic acid) Coverage Criteria

    Customize your policy alerts

    Sign up for blue cross blue shield - south dakota Policy 05.02.02 alerts

    Get alerted when Policy 05.02.02 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Prior authorization coverage for Ocaliva in adults with primary biliary cholangitis, requiring documented clinical criteria, specialist prescribing or consultation, required laboratory information, and no specified cirrhosis-related exclusions.

    Policy Summary
    PayerBlue Cross Blue Shield - South Dakota
    PolicyOcaliva (obeticholic acid) Coverage Criteria
    Policy CodePolicy 05.02.02
    Change TypeNo material change
    Effective DateDec 18, 2025
    Last ReviewOct 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization with the required pretreatment or current laboratory results and applicable clinical documentation.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    12 monthsInitial authorization duration
    12 monthsContinuation authorization duration
    30 tablets/30 daysQuantity limit
    2 of 3Diagnostic criteria for PBC

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Child-Pugh B or C
    Excluded cirrhosis example

    Coverage Criteria

    Initial Therapy

    Coverage may be granted for an authorization period of 12 months for treatment of primary biliary cholangitis (PBC) in patients 18 years of age or older when all of the following criteria are met:

    ALL of the following

    • ALL of the following

      • At least TWO of the following three criteria

        • Biochemical evidence of cholestasis with elevation of alkaline phosphatase (ALP) level for at least 6 months duration.
        • Presence of antimitochondrial antibodies (AMA) (titer > 1:40 by immunofluorescence or immunoenzymatic reactivity) or PBC-specific antinuclear antibodies (ANA), such as anti-gp210 or anti-sp100.
        • Histologic evidence of PBC on liver biopsy, such as nonsuppurative inflammation and destruction of interlobular and septal bile ducts.
      • Patient has an elevated serum ALP level prior to initiation of therapy with the requested drug.
      • At least ONE of the following

        • Inadequate response to at least 12 months of prior therapy with ursodeoxycholic acid (UDCA)/ursodiol, and the patient will continue concomitant therapy with UDCA/ursodiol.
        • Intolerance to UDCA/ursodiol.

    Continuation Therapy

    Coverage may be granted for an authorization period of 12 months when the patient has achieved or maintained a clinical benefit from Ocaliva therapy, as demonstrated by at least one of the following:

    At least ONE of the following clinical benefit criteria

    • Serum ALP level has decreased by at least 15%.>= 15% reduction in serum ALP level
    • Serum ALP level is less than 1.67 times the upper limit of normal (ULN).< 1.67 times ULN
    • Total bilirubin is less than or equal to the upper limit of normal (ULN).<= ULN

    Coverage will not be provided if the patient has decompensated cirrhosis, including Child-Pugh Class B or C disease, or has experienced a prior decompensation event.

    Coverage will not be provided if the patient has compensated cirrhosis with evidence of portal hypertension, including ascites, gastroesophageal varices, or persistent thrombocytopenia.

    Clinical Thresholds and Definitions

    ALP Elevation Duration
    RequirementBiochemical evidence of cholestasis with alkaline phosphatase (ALP) elevation
    Required durationAt least 6 months
    Diagnostic contextOne of three findings used to confirm primary biliary cholangitis (PBC)
    AMA Diagnostic Threshold
    TestAntimitochondrial antibody (AMA)
    Diagnostic thresholdTiter greater than 1:40
    Testing methodsImmunofluorescence or immunoenzymatic reactivity

    Authorization and Documentation Requirements

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required for Ocaliva. Submit the required documentation for both initial and continuation requests.

    • For initial requests, submit the pretreatment serum alkaline phosphatase (ALP) level.
    • For continuation requests, submit the current serum ALP and/or total bilirubin level.
    • Initial and continuation authorization may be granted for 12 months when applicable criteria are met.
    Documentation Required

    Qualified Specialist Prescriber Required

    Ocaliva must be prescribed by or in consultation with a qualified specialist.

    • Hepatologist
    • Gastroenterologist

    Policy Background

    Ocaliva (obeticholic acid) coverage applies to adults with primary biliary cholangitis (PBC) when the specified cirrhosis-related exclusions are absent. Coverage is subject to the policy’s clinical criteria, including appropriate UDCA/ursodiol treatment history or intolerance, required laboratory documentation, and specialist prescribing or consultation.

    Primary Biliary Cholangitis Definition

    Primary Biliary Cholangitis Definition
    Confirmation ruleAt least two of the three specified findings must be present
    Finding 1Biochemical cholestasis with ALP elevation for at least 6 months
    Finding 2Disease-specific antibodies, including AMA or PBC-specific ANA
    Finding 3Histologic evidence of PBC on liver biopsy

    Initial Approval

    Initial Approval

    Authorization of 12 months may be granted for adults when all of the following initial criteria are met:

    Initial approval requirements

    • PBC confirmation

      • Biochemical cholestasis: ALP is elevated for at least 6 months.>=6 months
      • Disease-specific antibodies: AMA titer is >1:40 by immunofluorescence or immunoenzymatic reactivity, or PBC-specific ANA is present, such as anti-gp210 or anti-sp100.AMA >1:40 when applicable

    Continuation Approval

    Continuation Approval

    Authorization of 12 months may be granted when clinical benefit has been achieved or maintained:

    Clinical benefit: The patient has achieved or maintained a clinical benefit from Ocaliva therapy.At least 15% reduction in serum ALP; serum ALP <1.67 times ULN; or total bilirubin <=ULN

    Prior UDCA/Ursodiol Therapy

    StepRequirementCoverage
    1Inadequate response to at least 12 months of prior UDCA/ursodiol therapy, with continuation of concomitant UDCA/ursodiol therapy; or intolerance to UDCA/ursodiol.Required for initial Ocaliva coverage

    Ocaliva Quantity Limit

    Quantity Limit
    MedicationOcaliva
    Quantity limit30 tablets
    Time periodPer 30 days
    Policy Summary
    PayerBlue Cross Blue Shield - South Dakota
    PolicyOcaliva (obeticholic acid) Coverage Criteria
    Policy CodePolicy 05.02.02
    Change TypeNo material change
    Effective DateDec 18, 2025
    Last ReviewOct 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization with the required pretreatment or current laboratory results and applicable clinical documentation.
    SourceLink
    On This Page
    Coverage CriteriaClinical Thresholds and DefinitionsAuthorization and Documentation RequirementsPolicy BackgroundPrimary Biliary Cholangitis DefinitionInitial ApprovalContinuation ApprovalPrior UDCA/Ursodiol TherapyOcaliva Quantity Limit
    Serum ALP Clinical Benefit
    Clinical benefit option 1At least a 15% reduction in serum ALP level
    Clinical benefit option 2Serum ALP level less than 1.67 times the upper limit of normal (ULN)
    ApplicationUsed to demonstrate clinical benefit for continuation of Ocaliva therapy
    Total Bilirubin Clinical Benefit
    Clinical benefit criterionTotal bilirubin level less than or equal to the upper limit of normal (ULN)
    Required comparisonAt or below the upper limit of normal
    ApplicationUsed to demonstrate clinical benefit for continuation of Ocaliva therapy
    Step Therapy

    UDCA/Ursodiol Prerequisite

    The patient must have an inadequate response to at least 12 months of prior ursodeoxycholic acid (UDCA)/ursodiol therapy and continue concomitant UDCA/ursodiol therapy, or have documented intolerance to UDCA/ursodiol.

    • Inadequate response requires at least 12 months of prior UDCA/ursodiol therapy.
    • Concomitant UDCA/ursodiol therapy must continue when approval is based on inadequate response.
    • Documented intolerance to UDCA/ursodiol may satisfy the prerequisite instead.
    Documentation Required

    Initial Approval Criteria

    For initial approval, confirm that the patient is at least 18 years old and has PBC confirmed by at least two of the required diagnostic criteria, an elevated pretreatment serum ALP level, and a qualifying UDCA/ursodiol history.

    • PBC diagnosis must be supported by at least two of: ALP elevation for at least 6 months, AMA or PBC-specific ANA, or liver-biopsy evidence of PBC.
    • The pretreatment serum ALP level must be elevated.
    • The patient must have either an inadequate response after at least 12 months of UDCA/ursodiol with continued concomitant therapy or documented UDCA/ursodiol intolerance.
    Denial Risk

    Decompensated Cirrhosis Exclusion

    Coverage will not be provided for patients with decompensated cirrhosis or a prior decompensation event.

    • Includes Child-Pugh Class B or C disease.
    • Includes any prior decompensation event.
    Denial Risk

    Portal Hypertension Exclusion

    Coverage will not be provided for compensated cirrhosis with evidence of portal hypertension.

    • Ascites
    • Gastroesophageal varices
    • Persistent thrombocytopenia
    Documentation Required

    Initial Laboratory Documentation

    For initial requests, submit the patient's pretreatment serum alkaline phosphatase (ALP) level as part of the prior authorization documentation.

    • Required for initial requests.
    Documentation Required

    Continuation Laboratory Documentation

    For continuation requests, submit the patient's current serum ALP and/or current total bilirubin level.

    • Required for continuation requests.
    Denial Risk

    Clinical Benefit Required for Continuation

    Continuation authorization requires evidence that the patient has achieved or maintained clinical benefit from Ocaliva therapy.

    • Examples include at least a 15% reduction in serum ALP level.
    • Serum ALP level less than 1.67 times the upper limit of normal (ULN).
    • Total bilirubin level less than or equal to the ULN.
    Histology:
    Liver biopsy demonstrates histologic evidence of PBC, such as nonsuppurative inflammation and destruction of interlobular and septal bile ducts.
  1. Pretreatment ALP: The patient has an elevated serum ALP level before initiation of the requested drug.Elevated serum ALP
  2. UDCA/ursodiol pathway

    • Inadequate UDCA response: The patient had an inadequate response to at least 12 months of prior UDCA/ursodiol therapy and will continue concomitant UDCA/ursodiol therapy.>=12 months prior therapy
    • UDCA intolerance: The patient is intolerant to UDCA/ursodiol.